License and Commercialization agreement between Pierre Fabre and ValenzaBio on an anti-IGF-1R antibody for the development of a novel treatment in Thyroid Eye Disease (TED)

(0)
BESTHESDA, Maryland and CASTRES, France, April 8, 2021 /PRNewswire/ -- The US biopharmaceutical company ValenzaBio and the French pharmaceutical group Pierre Fabre announced today the signing of a license agreement of a preclinical insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody, for the treatment of Thyroid Eye Disease (TED), an endocrine disease with unmet medical need. ValenzaBio received from Pierre Fabre the worldwide and exclusive rights to develop and commercialize, outside of oncology, the anti-IGF-1R antibody, discovered by Pierre Fabre at its Center of immunology located in Saint-Julien-en-Genevois (France), with the aim of treating patients suffering from TED. Other indications in rare diseases could also be developed by ValenzaBio. In parallel, Pierre Fabre is pursuing the development of its anti-IGF-1R ADC program (W0101) in oncology.

Related Keywords

Castres ,Midi Pyrees ,France ,Maryland ,United States ,French ,America ,Pierre Fabre ,Kostenloser Wertpapierhandel ,Nathalie Corva ,Eric Ducournau ,Patrickj Crutcher ,Oncology Research At Pierre Fabre ,Valenzabio Inc ,Pierre Fabre Group ,Pierre Fabre Foundation ,Thyroid Eye Disease ,Immuno Oncology Research ,North America ,Ecocert Environment ,பிரான்ஸ் ,மேரிலாந்து ,ஒன்றுபட்டது மாநிலங்களில் ,பிரஞ்சு ,அமெரிக்கா ,பியர் ஃபேப்ரே ,பியர் ஃபேப்ரே குழு ,பியர் ஃபேப்ரே அடித்தளம் ,தைராய்டு கண் நோய் ,இம்யூனோ புற்றுநோயியல் ஆராய்ச்சி ,வடக்கு அமெரிக்கா ,